Deep Track Capital’s Aligos Therapeutics ALGS Stock Holding History

Deep Track Capital’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.3M	Hold	444,110	–	–	0.05%	63
2025 Q4	$4.14M	Hold	444,110	–	–	0.07%	50
2025 Q3	$4.35M	Hold	444,110	–	–	0.12%	49
2025 Q2	$3.2M	Hold	444,110	–	–	0.1%	60
2025 Q1	$3.66M	Buy	444,110 +200,000	+82%	+$4.38M	0.12%	63
2024 Q4	$9.73M	Hold	244,110	–	–	0.36%	48
2024 Q3	$2.11M	Sell	244,110 -1	-0%	-$12	0.07%	68
2024 Q2	$2.14M	Hold	244,111	–	–	0.06%	66
2024 Q1	$5.98M	Hold	244,111	–	–	0.17%	58
2023 Q4	$4.05M	Buy	+244,111	New	+$4.2M	0.14%	59

Other funds holding ALGS

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Deep Track Capital's ALGS Position: Q1 2026 in Review

Deep Track Capital held its Aligos Therapeutics (ALGS) position steady in Q1 2026 at 444,110 shares worth $3.3M. The position accounts for 0.05% of the portfolio, ranked #63.

Deep Track Capital first reported a position in ALGS in Q4 2023 and has held it in 10 quarters since. The position peaked at $9.73M in Q4 2024. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

Deep Track Capital held 444,110 shares of Aligos Therapeutics worth $3.3M as of Q1 2026.
Deep Track Capital left its Aligos Therapeutics share count unchanged in Q1 2026.
Aligos Therapeutics made up 0.05% of Deep Track Capital's portfolio in Q1 2026, its #63 holding.
Deep Track Capital first reported a position in Aligos Therapeutics in Q4 2023 and has held it in 10 quarters since.
Deep Track Capital's Aligos Therapeutics position peaked at $9.73M in Q4 2024.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.